| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
796.44(B) |
| Last
Volume: |
1,747,701 |
Avg
Vol: |
3,278,293 |
| 52
Week Range: |
$434.7 - $815.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
505,762 |
1,375,762 |
3,014,918 |
5,975,430 |
| Total Sell Value |
$409,104,400 |
$1,016,789,780 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
10 |
22 |
49 |
89 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2020-02-01 |
4 |
D |
$139.64 |
$1,019,232 |
D/D |
(7,299) |
38,324 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2020-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,317 |
45,623 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2020-01-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
190,666 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2020-01-21 |
4 |
A |
$140.91 |
$1,973 |
D/D |
14 |
58,081 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-01-13 |
4 |
S |
$138.84 |
$28,478,495 |
D/D |
(205,000) |
113,720,304 |
|
-10% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-01-10 |
4 |
S |
$138.00 |
$28,979,013 |
D/D |
(210,000) |
113,925,304 |
|
-11% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-01-09 |
4 |
S |
$135.79 |
$29,874,729 |
D/D |
(220,000) |
114,135,304 |
|
-18% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-01-08 |
4 |
S |
$133.17 |
$23,018,105 |
D/D |
(172,650) |
114,355,304 |
|
-18% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-01-07 |
4 |
S |
$132.90 |
$4,338,579 |
D/D |
(32,645) |
114,527,954 |
|
-19% |
|
| Mason Michael B |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
865 |
|
21% |
|
| Mason Michael B |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,250 |
|
21% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-12-20 |
4 |
S |
$132.90 |
$2,618,812 |
D/D |
(19,705) |
114,560,599 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-12-18 |
4 |
S |
$128.84 |
$28,443,848 |
D/D |
(220,000) |
114,580,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-12-17 |
4 |
S |
$125.06 |
$27,023,552 |
D/D |
(215,000) |
114,800,304 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-12-16 |
4 |
A |
$122.85 |
$9,951 |
D/D |
81 |
2,921 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-12-16 |
4 |
A |
$122.85 |
$2,088 |
D/D |
17 |
58,067 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-12-16 |
4 |
A |
$122.85 |
$13,636 |
D/D |
111 |
11,152 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-12-16 |
4 |
A |
$122.85 |
$10,934 |
D/D |
89 |
46,909 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-12-09 |
4 |
S |
$119.70 |
$1,312,151 |
D/D |
(10,962) |
115,015,304 |
|
- |
|
| Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2019-12-06 |
4 |
AS |
$120.00 |
$3,000,000 |
I/I |
(25,000) |
33,414 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2019-12-06 |
4 |
AS |
$120.00 |
$540,000 |
D/D |
(4,500) |
29,306 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-12-06 |
4 |
S |
$120.15 |
$23,313,498 |
D/D |
(194,038) |
115,026,266 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-12-04 |
4 |
S |
$118.52 |
$24,890,040 |
D/D |
(210,000) |
115,220,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-27 |
4 |
S |
$117.51 |
$5,752,257 |
D/D |
(48,953) |
115,430,304 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2019-11-25 |
4 |
S |
$117.60 |
$12,855,797 |
D/D |
(109,318) |
115,535,986 |
|
- |
|
1437 Records found
|
|
Page 25 of 58 |
|
|
1.33 (0.16%) 
